JP6073244B2 - 部分フッ素化アルカンを含むo/wエマルション - Google Patents
部分フッ素化アルカンを含むo/wエマルション Download PDFInfo
- Publication number
- JP6073244B2 JP6073244B2 JP2013546732A JP2013546732A JP6073244B2 JP 6073244 B2 JP6073244 B2 JP 6073244B2 JP 2013546732 A JP2013546732 A JP 2013546732A JP 2013546732 A JP2013546732 A JP 2013546732A JP 6073244 B2 JP6073244 B2 JP 6073244B2
- Authority
- JP
- Japan
- Prior art keywords
- propofol
- emulsion
- composition
- partially fluorinated
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
Description
本発明は、(a)式RFRHまたはRFRHRFに従う部分フッ素化アルカンを含む分散相、(b)水性連続相、および(c)少なくとも1つの界面活性剤を含む、物理的に安定なO/Wエマルション形態の新規な液体組成物を提供し、ここで、RFは、20個以下の炭素原子を含む全フッ素化炭化水素セグメントであり、RHは、3〜20個の炭素原子を含む非フッ素化炭化水素セグメントである。全フッ素化化合物は、分散相には存在しない。この組成物は、分散相の平均液滴径が約1μmよりも小さいことをさらに特徴とする。
−ペグ化グリセリド、例えばマクロゴール−15−ヒドロキシステアレート(例、ソルトール(Solutol)(登録商標)HS15)、マクロゴールグリセロールリシノレエート−35(例、クレモフォール(Cremophor)(登録商標)EL)、マクロゴールグリセロールヒドロキシステアレート−40(例、クレモフォール(登録商標)RH40)、マクロゴール−1000−グリセロールモノラウレート、マクロゴール−1000−グリセロールモノステアレート、およびマクロゴール−1000−グリセロールモノオレエートなど;
−ペグ化脂肪酸、例えばマクロゴールステアレート400、ポリオキシル40ステアレート、およびポリオキシル60ステアレートなど;
−ペグ化脂肪アルコール、例えばマクロゴールラウリルエーテル、ポリオキシル20セトステアリルエーテル、およびポリオキシル10オレイルエーテルなど;
−ペグ化ソルビタン脂肪酸エステル、例えばポリソルベート20、ポリソルベート40、ポリソルベート60、およびポリソルベート80(例、Tween(登録商標)20/40/60/80)など;ならびに
−ポリオキシエチレンおよびポリオキシプロピレンのトリブロック共重合体、例えばポロキサマー124、ポロキサマー188、ポロキサマー237、ポロキサマー338、およびポロキサマー407などが挙げられる。上記から、ポリソルベートが特に好ましい。
実施例
Claims (9)
- (a)プロポフォールおよびF4H5またはF6H8から選択される部分フッ素化アルカンを含む分散相と;
(b)水性連続相と;
(c)少なくとも1つの界面活性剤と;
を含み、前記プロポフォールは前記部分フッ素化アルカン中に溶解し、前記分散層中のプロポフォールの濃度が少なくとも10重量%である、
物理的に安定なO/Wエマルションの形態の液体組成物であって、
かつ、前記分散相の平均液滴径は、1μmよりも小さい、液体組成物。 - 無菌であり、かつ/または加熱殺菌可能であることをさらに特徴とする、請求項1に記載の組成物。
- 非イオン性界面活性剤を含み、前記水性連続相が塩またはイオン化合物を含むことをさらに特徴とする、請求項1または2のいずれか一項に記載の組成物。
- イオン性界面活性剤を含み、前記水性連続相が、生理学的に許容される非イオン性浸透圧調整剤を含むことをさらに特徴とする、請求項1または2のいずれか一項に記載の組成物。
- 前記連続する水相が、緩衝液およびアミノ酸から選択される化合物を含む、請求項1〜4のいずれか一項に記載の組成物。
- 前記分散相中のプロポフォールの濃度が、10〜50重量%である、請求項1〜5のいずれか一項に記載の組成物。
- 麻酔の導入および/または維持に、または鎮静のために使用するための、請求項1〜6のいずれか一項に記載の組成物であって、前記使用が、前記組成物を必要とする患者への前記組成物の非経口投与を含む、組成物。
- 前記分散相が、前記エマルションの少なくとも50重量%に相当する、請求項1〜7のいずれか一項に記載の組成物。
- 医薬として使用するための、請求項1〜8のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11150064.1 | 2011-01-04 | ||
EP11150064 | 2011-01-04 | ||
PCT/EP2012/050043 WO2012093113A1 (en) | 2011-01-04 | 2012-01-03 | O/w-emulsions comprising semifluorinated alkanes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014501270A JP2014501270A (ja) | 2014-01-20 |
JP6073244B2 true JP6073244B2 (ja) | 2017-02-01 |
Family
ID=43978091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013546732A Expired - Fee Related JP6073244B2 (ja) | 2011-01-04 | 2012-01-03 | 部分フッ素化アルカンを含むo/wエマルション |
Country Status (15)
Country | Link |
---|---|
US (5) | US20140004197A1 (ja) |
EP (2) | EP2661280B1 (ja) |
JP (1) | JP6073244B2 (ja) |
KR (1) | KR101910213B1 (ja) |
CN (1) | CN103313729B (ja) |
AU (1) | AU2012204932B2 (ja) |
BR (1) | BR112013016661B1 (ja) |
CA (1) | CA2819988C (ja) |
DK (2) | DK2661280T3 (ja) |
ES (2) | ES2711760T3 (ja) |
MX (1) | MX353154B (ja) |
PL (2) | PL2661280T3 (ja) |
PT (2) | PT3202421T (ja) |
TR (2) | TR201808752T4 (ja) |
WO (1) | WO2012093113A1 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
EP2714008B1 (en) | 2011-05-25 | 2016-12-14 | Novaliq GmbH | Pharmaceutical composition for administration to nails |
PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
WO2013110621A1 (en) | 2012-01-23 | 2013-08-01 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
JP6039152B2 (ja) | 2012-09-12 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ素化アルカン組成物 |
GB2511028A (en) * | 2012-12-18 | 2014-08-27 | Univ Manchester Metropolitan | Nano emulsions, methods of forming the same and uses thereof |
EP2783703A1 (en) * | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
KR102272568B1 (ko) | 2013-07-23 | 2021-07-05 | 노바리크 게엠베하 | 안정화 항체 조성물 |
CA2941518A1 (en) * | 2014-03-03 | 2015-09-11 | Encore Vision, Inc. | Lipoic acid choline ester compositions and methods of use |
CN108349855B (zh) | 2015-09-30 | 2021-07-20 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
CN116172987A (zh) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
CN110678207A (zh) | 2017-04-21 | 2020-01-10 | 诺瓦利克有限责任公司 | 碘组合物 |
US10717691B2 (en) | 2017-05-05 | 2020-07-21 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
CN111372566A (zh) | 2017-09-27 | 2020-07-03 | 诺瓦利克有限责任公司 | 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物 |
CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
SG11202007858VA (en) | 2018-03-02 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
AU2019345929B2 (en) | 2018-09-27 | 2022-02-03 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
EP3912621A1 (en) * | 2020-05-19 | 2021-11-24 | tesa Labtec GmbH | Propofol for diagnosis of primary headache |
FR3112475B1 (fr) | 2020-07-20 | 2023-11-10 | Naos Inst Of Life Science | formulation écobiologique, compatible avec la vie cellulaire, utilisable dans les domaines cosmétiques, dermopharmaceutiques ou vétérinaires |
WO2022169520A1 (en) * | 2021-02-05 | 2022-08-11 | Epalex Corporation | Fospropofol methods and compositions |
DE102021005495A1 (de) | 2021-11-06 | 2023-05-11 | Kocher-Plastik Maschinenbau Gmbh | Trennvorrichtung |
DE102021005494A1 (de) | 2021-11-06 | 2023-05-11 | Kocher-Plastik Maschinenbau Gmbh | Trennvorrichtung |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077036A (en) * | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
FR2679150A1 (fr) * | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
DE19709704C2 (de) * | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
ES2211151T3 (es) * | 1998-08-19 | 2004-07-01 | Skyepharma Canada Inc. | Dispersiones acuosas inyectables de propofol. |
US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
EP1124416A1 (en) | 1999-03-15 | 2001-08-22 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
US6177477B1 (en) * | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
US6399087B1 (en) * | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
CA2446060A1 (en) * | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
EP1684724A4 (en) * | 2003-11-19 | 2008-04-02 | Barnes Jewish Hospital | IMPROVED DRUG DELIVERY |
MX2008001746A (es) | 2005-08-05 | 2008-04-07 | Bharat Serums & Vaccines Ltd | Composiciones de emulsion de propofol intravenosas que tienen eficacia de conservacion. |
TWI376239B (en) * | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
PL2110126T3 (pl) | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
-
2012
- 2012-01-03 AU AU2012204932A patent/AU2012204932B2/en active Active
- 2012-01-03 PL PL12700455T patent/PL2661280T3/pl unknown
- 2012-01-03 DK DK12700455.4T patent/DK2661280T3/en active
- 2012-01-03 TR TR2018/08752T patent/TR201808752T4/tr unknown
- 2012-01-03 EP EP12700455.4A patent/EP2661280B1/en active Active
- 2012-01-03 PL PL17159788T patent/PL3202421T3/pl unknown
- 2012-01-03 CA CA2819988A patent/CA2819988C/en active Active
- 2012-01-03 WO PCT/EP2012/050043 patent/WO2012093113A1/en active Application Filing
- 2012-01-03 MX MX2013007807A patent/MX353154B/es active IP Right Grant
- 2012-01-03 JP JP2013546732A patent/JP6073244B2/ja not_active Expired - Fee Related
- 2012-01-03 ES ES12700455T patent/ES2711760T3/es active Active
- 2012-01-03 EP EP17159788.3A patent/EP3202421B1/en active Active
- 2012-01-03 BR BR112013016661-4A patent/BR112013016661B1/pt active IP Right Grant
- 2012-01-03 CN CN201280004613.1A patent/CN103313729B/zh active Active
- 2012-01-03 ES ES17159788.3T patent/ES2675242T3/es active Active
- 2012-01-03 US US13/978,334 patent/US20140004197A1/en not_active Abandoned
- 2012-01-03 PT PT171597883T patent/PT3202421T/pt unknown
- 2012-01-03 DK DK17159788.3T patent/DK3202421T3/en active
- 2012-01-03 KR KR1020137018703A patent/KR101910213B1/ko active IP Right Grant
- 2012-01-03 TR TR2019/01309T patent/TR201901309T4/tr unknown
- 2012-01-03 PT PT12700455T patent/PT2661280T/pt unknown
-
2017
- 2017-04-19 US US15/491,521 patent/US20170216204A1/en not_active Abandoned
-
2019
- 2019-01-28 US US16/259,037 patent/US20190224123A1/en not_active Abandoned
-
2020
- 2020-04-30 US US16/863,918 patent/US20200360285A1/en not_active Abandoned
-
2022
- 2022-12-23 US US18/146,306 patent/US20230139672A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6073244B2 (ja) | 部分フッ素化アルカンを含むo/wエマルション | |
US6726919B2 (en) | Injectable dispersion of propofol | |
JP5668004B2 (ja) | 2,6−ジイソプロピルフェノール(プロポフォール)の水性医薬組成物およびその使用 | |
US7915317B2 (en) | Aqueous 2,6-diisopropylphenol pharmaceutical compositions | |
RU2460516C2 (ru) | Офтальмические эмульсии масло-в-воде, содержащие простагландины | |
JP2006504771A (ja) | システインを伴うプロポフォール | |
US20100041769A1 (en) | Stable and ready-to-use oil-in-water propofol microemulsion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141120 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151029 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160428 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161026 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20161101 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170104 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6073244 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |